当前位置: X-MOL 学术Stem Cell Res. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Multipotent adult progenitor cells grown under xenobiotic-free conditions support vascularization during wound healing.
Stem Cell Research & Therapy ( IF 7.5 ) Pub Date : 2020-09-07 , DOI: 10.1186/s13287-020-01912-3
Bart Vaes 1 , Ellen Van Houtven 1 , Ellen Caluwé 2 , Aernout Luttun 2
Affiliation  

Cell therapy has been evaluated pre-clinically and clinically as a means to improve wound vascularization and healing. While translation of this approach to clinical practice ideally requires the availability of clinical grade xenobiotic-free cell preparations, studies proving the pre-clinical efficacy of the latter are mostly lacking. Here, the potential of xenobiotic-free human multipotent adult progenitor cell (XF-hMAPC®) preparations to promote vascularization was evaluated. The potential of XF-hMAPC cells to support blood vessel formation was first scored in an in vivo Matrigel assay in mice. Next, a dose-response study was performed with XF-hMAPC cells in which they were tested for their ability to support vascularization and (epi) dermal healing in a physiologically relevant splinted wound mouse model. XF-hMAPC cells supported blood vessel formation in Matrigel by promoting the formation of mature (smooth muscle cell-coated) vessels. Furthermore, XF-hMAPC cells dose-dependently improved wound vascularization associated with increasing wound closure and re-epithelialization, granulation tissue formation, and dermal collagen organization. Here, we demonstrated that the administration of clinical-grade XF-hMAPC cells in mice represents an effective approach for improving wound vascularization and healing that is readily applicable for translation in humans.

中文翻译:

在无异源条件下生长的多能成年祖细胞支持伤口愈合过程中的血管形成。

在临床前和临床上已经对细胞疗法进行了评估,以此作为改善伤口血管形成和愈合的一种手段。理想情况下,将这种方法转换为临床实践需要使用无临床级无异生素的细胞制剂,但大多数缺乏证明后者无临床前功效的研究。在此,评估了不含异生物素的人类多能成年祖细胞(XF-hMAPC®)制剂促进血管生成的潜力。XF-hMAPC细胞支持血管形成的潜力首先在小鼠体内Matrigel分析中进行了评分。接下来,对XF-hMAPC细胞进行了剂量反应研究,其中测试了它们在生理相关的夹层伤口小鼠模型中支持血管形成和(epi)皮肤愈合的能力。XF-hMAPC细胞通过促进成熟(平滑肌细胞包裹)血管的形成来支持Matrigel中的血管形成。此外,XF-hMAPC细胞剂量依赖性地改善了伤口血管形成,与伤口闭合和再上皮形成,肉芽组织形成和真皮胶原组织的增加有关。在这里,我们证明了在小鼠中临床级XF-hMAPC细胞的给药代表了一种有效的方法,可以改善伤口的血管形成和愈合,很容易应用于人类的翻译。和真皮胶原组织。在这里,我们证明了在小鼠中临床级XF-hMAPC细胞的给药代表了一种有效的方法,可以改善伤口的血管形成和愈合,很容易应用于人类的翻译。和真皮胶原组织。在这里,我们证明了在小鼠中临床级XF-hMAPC细胞的给药代表了一种有效的方法,可以改善伤口的血管形成和愈合,很容易应用于人类的翻译。
更新日期:2020-09-08
down
wechat
bug